Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $529,500.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of the company's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $52.95, for a total transaction of $529,500.00. Following the completion of the sale, the insider owned 91,488 shares in the company, valued at approximately $4,844,289.60. This trade represents a 9.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, June 18th, Catriona Yale sold 1,633 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.84, for a total transaction of $89,553.72.
• On Monday, June 16th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.23, for a total transaction of $542,300.00.
• On Tuesday, June 10th, Catriona Yale sold 2,803 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.00, for a total transaction of $151,362.00.
• On Thursday, May 15th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $39.30, for a total transaction of $393,000.00.

Akero Therapeutics Trading Down 4.1%

Shares of AKRO stock traded down $2.25 during trading hours on Friday, reaching $52.08. 881,281 shares of the stock were exchanged, compared to its average volume of 1,055,214. Akero Therapeutics, Inc. has a 12-month low of $21.34 and a 12-month high of $58.40. The company has a current ratio of 16.80, a quick ratio of 16.80 and a debt-to-equity ratio of 0.03. The company's 50-day moving average price is $50.63 and its 200-day moving average price is $44.46. The firm has a market capitalization of $4.15 billion, a price-to-earnings ratio of -26.71 and a beta of -0.15.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported $0.90 earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $1.91. As a group, equities analysts anticipate that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Citigroup decreased their price target on shares of Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Bank of America increased their price target on shares of Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a research report on Tuesday, May 27th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $82.50.

Institutional Trading of Akero Therapeutics

Several large investors have recently made changes to their positions in AKRO. Tema Etfs LLC acquired a new position in Akero Therapeutics during the fourth quarter worth $894,000. Principal Financial Group Inc. acquired a new position in Akero Therapeutics during the first quarter worth $10,404,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $840,000. RTW Investments LP raised its position in shares of Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company's stock valued at $190,840,000 after buying an additional 940,388 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $422,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.